Next Article in Journal
Clinical Response of Metastatic Breast Cancer to Multi-targeted Therapeutic Approach: A Single Case Report
Next Article in Special Issue
Molecular Epidemiology of Female Lung Cancer
Previous Article in Journal
Breast Cancer-Initiating Cells: Insights into Novel Treatment Strategies
Previous Article in Special Issue
Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases
Article Menu

Export Article

Open AccessReview
Cancers 2011, 3(1), 1426-1453; doi:10.3390/cancers3011426

The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer

Trinity College Dublin, Department of Clinical Medicine, Trinity Centre for Health Sciences, St James Hospital, James Street, Dublin 8, Ireland
*
Author to whom correspondence should be addressed.
Received: 29 December 2010 / Revised: 9 March 2011 / Accepted: 10 March 2011 / Published: 17 March 2011
(This article belongs to the Special Issue Lung Cancer)
View Full-Text   |   Download PDF [308 KB, uploaded 17 March 2011]   |  

Abstract

Non-small cell lung cancer (NSCLC) is the most common cause of cancer related death in the world. Cisplatin and carboplatin are the most commonly used cytotoxic chemotherapeutic agents to treat the disease. These agents, usually combined with drugs such as gemcitabine or pemetrexed, induce objective tumor responses in only 20–30% of patients. Aberrant epigenetic regulation of gene expression is a frequent event in NSCLC. In this article we review the emerging evidence that epigenetics and the cellular machinery involved with this type of regulation may be key elements in the development of cisplatin resistance in NSCLC. View Full-Text
Keywords: epigenetics; histone; post-translational modification; DNA methylation; epigenetic modifiers; cisplatin; NSCLC epigenetics; histone; post-translational modification; DNA methylation; epigenetic modifiers; cisplatin; NSCLC
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

O’Byrne, K.J.; Barr, M.P.; Gray, S.G. The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer. Cancers 2011, 3, 1426-1453.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top